Viska addresses the problem that up to 85% of solid tumors - especially glioblastoma - are resistant to current cancer immunotherapies. Our initial asset targets glioblastoma, colorectal, and non-small cell lung cancer. Second and third assets are in development for hematologic cancers and triple-negative breast cancer.

We’ve demonstrated that our lead asset VISK-103 inhibits the growth of glioblastoma and colorectal cancer in animal models, with additional in vitro evidence for non-small cell lung cancer. Administering VISK-103 in combination with anti-PD1 enhances the checkpoint inhibitor’s efficacy. 

Our proprietary nanobody-enzyme fusion protein delivers a potent dose of superoxide into the tumor microenvironment, directly killing cancer cells and triggering an immune response specific to the tumor. Viska’s modular technology enables exchange of the nanobody, allowing Viska to target several cancer indications.